# The causal inference paradigm for network meta-analysis with implications for feasibility and practice

Mireille E. Schnitzer,\*

Faculté de pharmacie, Université de Montréal

Russell J. Steele,

Department of Mathematics and Statistics, McGill University Michèle Bally,

Department of Epidemiology, Biostatistics and Occupational Health, McGill University

and Ian Shrier,

Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, McGill University

March 27, 2022

#### Abstract

While standard meta-analysis pools the results from randomized trials that compare two specific treatments, network meta-analysis aggregates the results of randomized trials comparing a wider variety of treatment options. However, it is unclear whether the aggregation of effect estimates across heterogeneous populations will be consistent for a meaningful parameter. Drawing from counterfactual theory and the causal inference framework, we define the population of interest in a network metaanalysis and define the target parameter under a series of a priori nonparametric structural assumptions. This allows us to determine the requirements for identifiability of this parameter, enabling a description of the conditions under which network meta-analyses are feasible. We then propose several modeling strategies, including a novel Bayesian hierarchical random effects model, for consistent estimation of the intervention-specific mean outcome and model-independent contrasts between treatments.

*Keywords:* Bayesian inference, clinical trials, counterfactuals, propensity score, systematic review.

<sup>\*</sup>This work was partially supported by the *Fonds de recherche en santé du Québec* [Research Scholar Junior 1 Grant to MES] and the Natural Sciences and Engineering Research Council of Canada [Individual Discovery Grant to RJS]

## 1 Introduction

In many areas, researchers model networks of randomized controlled trials (RCT) by aggregating multiple sources of evidence in order to offer a more generalizable and precise evaluation of comparisons between treatments for a given condition (Lumley, 2004; Salanti et al., 2008; Caldwell et al., 2005; Lu and Ades, 2004). When many treatments for a common condition are tested and made available over time, the medical literature may then contain multiple RCTs with various treatment comparisons on potentially different subpopulations. A network meta-analysis aggregates the results from the relevant RCTs in order to obtain an estimate of the contrast between each pair of treatments. In particular, indirect information about any given contrast of interest may be obtained from RCTs that did not compare the two treatments of interest directly.

The multiple RCTs included in the network may be performed on populations that differ in terms of their baseline characteristics. Population-specific variables may affect the response to treatment so that in order to combine inference involving the means, it might be beneficial to control for such variables (Salanti et al., 2009). Furthermore, it has been noted that if these characteristics not only differentially affect response to treatment, but also the initial study design choice of which treatments to compare, then these variables may confound the overall effect estimate (Jansen et al., 2012).

We illustrate these ideas with the following example from infectious disease research. An increase in methicillin-resistant *Staphylococcus aureus* (MRSA) has spurred investigation of comparative efficacy of different treatment options. While the antibiotic vancomycin has been the standard treatment for many decades, treatment failures have been noted in patients with serious infections (Liu et al., 2011). Interest therefore lies in whether alternative antibiotics are as effective as the standard. Bally et al. (2012) performed a systematic review and Bayesian network meta-analyses of RCTs of parenteral antibiotics used for treating hospitalized adults with complicated skin and soft-tissue infections (cSSTIs) and hospital-acquired or ventilator-associated pneumonia. The target population of interest is the population of clinical trial participants with suspected or proven MRSA cSSTIs or pneumonia, with corresponding studies published until May 2012. The site of infection represents an important difference in the entrance criteria of the various studies: 13 studies

enrolled subjects with cSSTIs and 6 studies enrolled subjects with hospital-acquired or ventilator-associated pneumonia. The original network meta-analysis of Bally et al. (2012) considered these two infection types in separate analyses. If one could control for study-level confounders, a higher-level yet still clinically interesting question could be asked: "Are the alternative therapies as effective as the standard antibiotic for the treatment of MRSA?" Because infection site and year can potentially affect the choice of investigated therapies and the outcomes, our proposed methodology indicate that both confounders must be and can be adjusted for.

In this paper, we propose a novel definition of the target causal parameter of interest for network meta-analysis and delineate the assumptions required to estimate this parameter in the presence of measured confounders. We are then able to clarify conditions under which a network meta-analysis is appropriate and when it might mislead decision making. In Section 2, we define the target parameters through the Neyman-Rubin counterfactual model (Rubin, 1974), list and discuss the assumptions needed for the estimation of the mean outcome under a specified treatment, and propose a study-level directed acyclic graph. In Section 3, we derive the G-formula to determine the assumptions needed for identifiability. In Section 4, we describe several estimation methods adapted from the single study causal inference setting and also a novel Bayesian hierarchical model. In Section 5, we compare these methods with some alternatives under two different data-generating mechanisms. In Section 6 we perform a reanalysis of the systematic review by Bally et al. (2012) to compare the efficacy of antibiotics on MRSA in hospitalized patients. Section 7 concludes with a discussion of potential complications and future directions.

## 2 The arm-specific counterfactual perspective

### 2.1 Notation and definitions

An individual RCT can be viewed as a set of two (or more) distinct studies, with each study receiving a different treatment. Each RCT is run on a subject sample that represents a wider population, called a *superpopulation*. The superpopulations targeted by the RCTs may differ in terms of their characteristics due to each trial's physical and temporal location, the individual inclusion and exclusion criteria, and the recruitment targets. Due to randomization of the treatment assignment and assuming that each RCT collected a random sample of their target superpopulation, the participants of each study arm are representative of the RCT-specific superpopulation.

More formally, the superpopulation is the conceptual group of essentially infinite size from which the study sample is selected (Robins, 1988). A measure of some outcome (Y) is taken on each subject in the RCT arm. In this article, we will generally consider the example where the sample mean and standard deviation of Y are the summary statistics of interest in each RCT, unless otherwise stated. Let  $Y^a$  be the potential (or counterfactual) outcome of a generic subject had that subject received treatment A = a. In an RCT, each study arm produces an estimate of the superpopulation-specific mean of the outcome  $Y^a$  under the treatment assigned. Let the true mean of the potential outcome under treatment a be denoted  $M_i^a := E(Y^a \mid P_i)$  where  $P_i$  represents membership in the superpopulation targeted in study i. Let  $\Sigma_i^a := \sqrt{Var(Y^a \mid P_i)}$  be the standard deviation of the potential outcomes in  $P_i$  under treatment a. Now suppose that each superpopulation is independently drawn from a metapopulation,  $\mathcal{P} = \bigcup_{i=1}^{N} P_i$ , the union of all possible superpopulations. The ultimate target of an unconditional metaanalysis is  $M^a := E(Y^a) = E(M_i^a)$ , which represents the mean outcome under treatment a on the metapopulation. The standard deviation of the overall outcome distribution is  $\Sigma^{a} := \sqrt{Var(Y^{a})} = \sqrt{E\{Var(Y^{a} \mid P_{i})\} + Var\{E(Y^{a} \mid P_{i})\}} = \sqrt{E(\Sigma_{i}^{a}) + Var(M_{i}^{a})},$ representing the within and between study heterogeneity in the outcome under treatment.

For two different treatments, A = a or b, with corresponding means  $M^a$  and  $M^b$ , we can define a causal effect as the contrast between the mean outcome when the entire metapopulation is treated according to one treatment versus another. For instance, for binary outcomes we may define the causal risk difference as  $M^a - M^b$  and the causal risk ratio as  $M^a/M^b$ .

Let  $A_{ij}$  be the intervention received by subjects in arm j of a particular RCT indexed by i. For this arm, we observe an estimated mean outcome  $\bar{Y}_{ij}$  and standard deviation  $S_{ij}$ , where  $\bar{Y}_{ij}$  is an unbiased estimate of  $M_i^{A_{ij}}$  and  $S_{ij}$  is a consistent estimate of  $\Sigma_i^{A_{ij}}$ . Let  $O_i = (n_i, W_i, \{N_{ij}, A_{ij}, \bar{Y}_{ij}, S_{ij}\}; j = 1, ..., n_i), i = 1, ..., N$  where  $n_i$  is the number of arms in the study and  $W_i$  is study baseline information. For the j-th arm of RCT i, let  $N_{ij}$  be the number of subjects and N be the total number of RCTs in the sample. We assume that the individual  $O_i$  vectors are independently drawn from the infinite metapopulation and identically distributed. The quantity  $\bar{Y}_{ij}^a$  can be defined as the Neyman-Rubin (Rubin, 1974) counterfactual outcome for the j-th arm of RCT i under treatment a. Note that  $E(\bar{Y}_{ij}^a \mid P_i) = E(\bar{Y}_{ij'}^a \mid P_i) = M_i^a$  for  $j \neq j'$  because each  $\bar{Y}_{ij}^a, j = 1, ..., n_i$  is sampled from the same superpopulation  $P_i$ . In general, however, due to randomization variability at the RCT level,  $\bar{Y}_{ij}^a \neq \bar{Y}_{ij'}^a$  when  $j \neq j'$ .

As mentioned above, each study arm in an RCT is representative of the superpopulation related to that RCT. However, the patient sample in the study arm may not be representative of the metapopulation. In addition, because treatment was not randomly allocated across different RCTs, the collection of mean outcomes observed under a given treatment *a* may not be representative of the metapopulation under treatment *a*. At the design stage, the decision of which treatments to include as arms within an RCT may be influenced by the characteristics of the superpopulation on which the study is taking place. For instance, consider the example of planning a study for a superpopulation with higher disease severity from Jansen, Schmid, and Salanti (2012). Studies including patients with severe disease are more likely to include an arm with an aggressive treatment. If this occurs, the mean outcome under the aggressive treatment may be different than in a less severe superpopulation. In this situation, we would say that the treatment-mean outcome relationship is confounded at the study level by severity.

### 2.2 Past approaches to network meta-analysis

As in the standard causal inference framework, it is helpful to think of network metaanalysis as a missing data problem. We require that each superpopulation had the potential to be assigned each treatment under investigation. Therefore, we can imagine that the complete data for each study includes mean estimates for each treatment. The available data only includes estimates for the treatments that were actually evaluated in the study.

The standard approaches in network meta-analysis have placed a hierarchical model on either the study-specific contrasts (e.g. the difference in means) or on the arm-specific outcomes (e.g. the proportion of subjects in a study arm with the event of interest) and specified a within-study correlation structure (Lu and Ades, 2004; Salanti et al., 2008; Dias et al., 2013). A priori (Cope et al., 2014) and post-hoc (Lu and Ades, 2006) investigation of the homogeneity of effect estimates produced by the direct and indirect treatment contrasts is routinely recommended.

The effect targeted in a hierarchical model depends on the contrast-type chosen and the parametrization of the model, and may or may not correspond to a marginal effect as described above. For binary outcomes, due to the non-collapsibility of the logistic regression model (Gail et al., 1984) in particular, adjustment for covariates in such a model changes the true value of the "effect" parameter being estimated. This type of modeling strategy may therefore be biased for the estimation of a marginal effect. For binary outcomes, Zhang et al. (2014) model the arm-specific outcomes using a Bayesian hierarchical model to estimate treatment-specific event rates. This approach allows for the estimation of marginal effects when the superpopulations are homogeneous but does not easily adapt to covariate adjustment under heterogeneity.

In order to facilitate the decision of which variables to control for, Jansen, Schmid, and Salanti (2012) (hereafter JSS) introduced the notion of adapting Pearl's causal directed acyclic graphs (DAGs) to this setting (Pearl, 2009). As a general rule, JSS advocate for the adjustment of all modifiers of the relative treatment effects across comparisons. They also discourage adjustment for covariates that are not effect modifiers due to the fact that they may *induce* bias in the meta-analysis. Both of these results, they conclude, can be read off of the DAGs. The JSS DAGs contain two primary nodes: one that represents the treatment comparison that is made in a particular study, and the second that represents the value of the contrast being estimated. This contrast, which might be a risk ratio or odds ratio for instance, is specific to the choice of treatment comparison that is made for the study in question. Therefore, they consider that the choice of treatment comparison "alters" the effect being measured and represent this in their DAG.

## 2.3 A Novel Causal Directed Acyclic Graph (DAG) for network meta-analysis

Similar to Alonso et al. (2014), we assume that heterogeneity in the different superpopulations targeted in the individual RCTs implies that each RCT estimates a different causal effect. Like Zhang et al. (2014), we take an "arm-based" approach to the problem. Like JSS, we draw a causal DAG in order to conceptualize the relationship between treatment, study results, and population-specific characteristics. For clarity, we assume that all studies contain two arms. We arbitrarily choose to intervene on the arm labeled j in each study. We write  $N_i = \{N_{ij}, j = 1, ..., n_i\}$ , the vector of sample sizes across arms. We will also define  $A_i = \{A_{ij}, j = 1, ..., n_i\}$ , the vector of treatment assignments evaluated in study i, and  $A_{i\setminus j}$  to mean the treatment vector excluding arm j.

Many of the assumptions presented in detail in Section 2.4 are drawn explicitly using the study-level DAGs in Figure 1(a). The nodes of the DAG represent variables measured at the level of the RCT and the arrows between them represent the effect of the parent on the child node. For example, the absence of an arrow from  $A_{i\setminus j}$  to  $\bar{Y}_{ij}$ ,  $S_{ij}$  represents a component of the "no interference" assumption that the treatment in one arm will not affect the outcome in another. The arrow from  $N_{ij}$  to  $\bar{Y}_{ij}$ ,  $S_{ij}$  is present because the sample size within a study arm will affect the distribution of the outcome summary statistics.

The sample size node  $N_{ij}$  is determined by the sample size calculation made in the study design phase and also by the success of recruitment. This calculation is inherently conditional on the superpopulation being evaluated, as superpopulation characteristics are taken into account when hypothesizing an effect size and standard error. This calculation is also conditional on the treatments being compared.

Causal DAGs can be used as a tool to identify which variables must be controlled for in the meta-analysis in order to estimate the treatment-specific metapopulation mean outcome. Depending on some underlying statistical assumptions that we will investigate in detail in the following sections, these DAGs may simplify to Figure 1(b). This happens because we can ignore the mediation path through  $N_{ij}$ . Under these conditions, assuming independence between the variables in  $W_i$ , the analysis must adjust for all common causes of treatment selection and study outcome distribution. Note that the recommendations for estimation and adjustment based on this DAG differ from those of JSS, who say that the analysis must adjust exclusively for effect modifiers. The assumptions that we list in Section 2.4 are explicitly required in the steps we take in Section 3 in order to determine (or simplify) the identifiability of the meta-analysis parameter of interest. The DAGs in JSS are drawn at the contrast levels, rather than separately for each arm as we do here. Specifically, rather than define  $\bar{Y}_{ij}$  as the outcome node, their outcome is the relative treatment effect. Their approach appeals to the traditional interpretations of DAGs in order to determine a sufficient confounder set, although we note that their DAGs do not conform to the classical DAG framework of (Pearl, 2009)



Figure 1: a) The study-level DAG reflecting the unconfoundedness and time-ordering assumptions made in Sections 2.4 and 3 without assuming independence between the sample mean and standard deviation within a study arm. b) The simplified DAG that arises from assuming the independence between the sample mean and standard deviation. Here,  $W1_i$ ,  $W2_i$  and  $W3_i$  are baseline covariates,  $A_{ij}$  and  $A_{i\setminus j}$  are the treatments assigned to arms jand the non-j arm(s), respectively,  $N_{ij}$  is the sample size of arm j,  $\bar{Y}_{ij}$  is the mean outcome and  $S_{ij}$  is the estimated standard error of the outcome of arm j.

#### 2.4 Assumptions

Here we clarify the assumptions needed for the identification and estimation of  $M^a$ , the metapopulation mean outcome, corresponding with the DAGs in Figure 1. These assump-

tions are sufficient for a binary outcome, where  $\bar{Y}_{ij}$  represents the proportion of subjects who experienced the outcome. For a continuous (or other) outcome, where the reported summary statistics are  $\bar{Y}_{ij}^a$  and  $S_{ij}^a$ , these are sufficient assumptions if we make the additional assumption that  $\bar{Y}_{ij}^a \perp S_{ij}^a \mid N_{ij}^a, W_i$  (see Section 3). We also comment on the meaning and plausibility of these assumptions in the hypothetical situation where each individual RCT has full compliance. Under full compliance, each RCT arm produces a consistent estimate of the mean outcome in the superpopulation under full adherence to the assigned treatment.

No interference. The use of the above counterfactual notation presupposes that the treatment assigned to one study does not affect the counterfactual outcome of another study (Rubin, 1980). A secondary level of interference within an individual study involves the treatment in one study arm affecting the outcomes in another study arm. This means that the estimates  $\bar{Y}_{ij}^a$  and  $S_{ij}^a$  do not depend on the treatment received by another arm of the same RCT. The assumption of no interference will generally not hold for studies of infectious disease. For example, an effective vaccine in one arm may impact the outcome of an unvaccinated subject in the control arm, because the unvaccinated subject will be less likely to be exposed to the disease through herd immunity.

Unconfoundedness. (Weak) unconfoundedness (Imbens, 2000) is required for the identification of  $M^a$ . In this context, unconfoundedness is the assumption that the counterfactual sample means under a treatment a are independent of the true treatment received conditional on measured covariates. Specifically, this means that  $\bar{Y}^a_{ij} \perp A_{ij} = a \mid W_i$ . As is common in applied causal analysis, we can intuitively think of this as the requirement of measuring all factors that can affect treatment decision and the outcome. In the DAG of Figure 1(a), this corresponds to measuring all the components of node  $W2_i$ . The validity of this assumption is entirely dependent on the subject-matter, how RCTs in the field are designed, and on the information across RCTs.

Consistency. The consistency assumption in this context states that the counterfactual mean of a study arm under a given treatment is the same as the observed result. With notation, this is equivalent to stating that  $\bar{Y}_{ij}^a = \bar{Y}_{ij}$  when  $A_{ij} = a$ .

Since our framework consists of a collection of RCTs, each treatment is expected to

be clearly defined and assigned to the individual and, subsequently, to the treatment arm. Having different definitions of treatment across studies may violate this assumption if all are categorized under the same treatment type and this variation has an impact on the outcome (Cole and Frangakis, 2009). For example, there may be different drug dosages and lengths of follow-up across studies. Disregarding these differences will violate consistency if the various treatment-types have differential effects on the patient outcomes. (Note that this definition of consistency corresponds with the causal assumption and is distinct from the network meta-analysis meaning of the term in e.g. Lu and Ades 2006.)

Positivity. Finally, we need to evaluate both theoretical and practical positivity. Theoretical positivity is the assumption that a study on any superpopulation has a positive probability of being assigned each treatment under investigation. Practical positivity is the condition that for every level of the characteristics  $W_i$ , there is an *estimated* positive probability of having received treatment.

Regarding positivity, a key feature of the target parameter  $M^a = E(M_i^a)$  is that it relies on the definition of the metapopulation  $\mathcal{P}$ . Due to heterogeneity in the network of RCTs, some trials may contain subjects who have a contraindication for a given a. If we define the metapopulation based on the collection of RCTs, the mean outcome  $M^a$ would not exist because a subset of the patients in that metapopulation could never have received this treatment. It therefore is incoherent to define the target parameter based on this metapopulation. However, it is possible to define inclusion and exclusion criteria for the metapopulation itself. In particular, we would have to exclude all studies that contain subjects for whom any treatment of interest is contraindicated. It is furthermore important to note that treatment comparisons must be made based on the same  $\mathcal{P}$ , so the metapopulation must be clearly defined to characterize the subjects who could receive both treatments.

## 3 The G-formula and identifiability

In order to identify  $M^a$ , the metapopulation parameter of interest, we must carefully describe the way the data are generated during the study design stage and then during the study. The independence assumptions used in this section are described in Section 2.4. At the study design stage for RCT *i*, the sub-population  $\mathcal{P}_i$  is drawn, which defines the population-level covariates  $W_i$ . The number of study arms  $n_i$  and the treatments compared in the study, the multivariate  $A_i = \{A_{ij}, j = 1, ..., n_i\}$ , are drawn conditional on  $W_i$ .

The sample size calculation is carried out based on the choice of treatment comparison and on the sub-population characteristics (i.e. based on the expected effect and precision in that sub-population). This calculation is approximate and the resulting sample size also depends on the success of recruitment. Therefore, the sample sizes for the treatment arms,  $N_{ij}$ , is not deterministic, but is drawn conditional on  $A_i$ ,  $n_i$  and  $W_i$ .

The second stage operates at the individual level once subjects are recruited and randomly assigned treatment. Suppose each subject k in arm j of study i has continuous outcome  $Y_{ijk}, k = 1, ..., N_{ij}$  (under treatment  $A_{ij}$ ). Each  $Y_{ijk}$  is independently drawn from a distribution with mean  $M_i^{A_{ij}}$  and standard deviation  $\Sigma_i^{A_{ij}}$ . The empirical mean outcome in arm j of study i is therefore  $\overline{Y}_{ij} = 1/N_{ij} \sum_k Y_{ijk}$ . The standard deviation is estimated as  $S_{ij}^2 = 1/(N_{ij} - 1) \sum_k (Y_{ijk} - \overline{Y}_{ij})^2$ . In addition, subject recruitment yields summary characteristics of the superpopulation, which we assume to include complete information about the covariates  $W_i$  that were known at study conception and contributed to the treatment choice. We assume in the following that we do not observe the subject-level data.

Let  $\omega_{ij}$  represent the set of estimated summary statistics from study *i* arm *j*. For instance, we might have that  $\omega_{ij} = {\bar{Y}_{ij}, S_{ij}}$ . Correspondingly, let  $\omega_{ij}^a$  be the set of estimates of the counterfactual summary statistics.

Assuming no interference between arms and that the outcome distribution in one arm of a study is conditionally independent of the outcomes in the others and also independent of the total number of arms, the probability density function  $f(O_i)$  of the observed data can be decomposed as

$$f(O_i) = Q_W(W_i)Q_n(n_i \mid W_i)g_A(A_i \mid n_i, W_i) \times \prod_{j=1}^{n_i} Q_N(N_{ij} \mid A_{ij}, A_{i\backslash j}, n_i, W_i)Q_\omega(\omega_{ij} \mid N_{ij}, A_{ij}, W_i)$$

where  $Q_W(W_i)$  corresponds to the density function for  $W_i$ ,  $Q_n(n_i | W_i)$  corresponds to the density function for  $n_i$  conditional on  $W_i$ , and  $g_A(A_i | n_i, W_i)$  corresponds to the conditional density function for  $A_i$ . Within each RCT,  $Q_N(N_{ij} | A_{ij}, A_{i\setminus j}, n_i, W_i)$  corresponds to the conditional density function for  $N_{ij}$  and  $Q_{\omega}(\omega_{ij} \mid N_{ij}, A_{ij}, W_i)$  is the conditional (joint) density for the measured outcome(s) in arm j. In particular, we assume here that common distributional forms exist across RCTs and study arms.

Fixing a treatment strategy a to an arbitrary arm determines which counterfactuals and what baseline study information are observed in the study. In other words, we set  $A_{ij} = a$  for a single arbitrary arm j. The resulting counterfactuals represent the random variables that would exist had the treatment been imposed for one of the arms (and the number of other arms and their treatment assignments were random). The joint density for the counterfactual data  $O_i^a = (W_i, n_i, A_{i\setminus j}^a, \{\omega_{ij^*}^a, N_{ij^*}^a, j^* = 1, ..., n_i\})$  can be obtained through the G-formula (Robins, 1986). This joint density function can be written as

$$\begin{split} f(O_i^a) = &Q_W(W_i)Q_n(n_i \mid W_i)g_{A\setminus j}(A_{i\setminus j}^a \mid n_i, W_i)Q_N(N_{ij}^a \mid A_{i\setminus j}^a, n_i, W_i)Q_\omega(\omega_{ij}^a \mid N_{ij}^a, W_i) \times \\ &\prod_{j^* \neq j} Q_\omega(\omega_{ij^*}^a \mid N_{ij^*}^a, A_{ij^*}^a, W_i)Q_N(N_{ij^*}^a \mid A_{i\setminus j}^a, n_i, W_i) \end{split}$$

where  $g_{A\setminus j}(A^a_{i\setminus j} \mid n_i, W_i)$  is defined as the conditional (joint) density of the treatments assigned to non-*j* arms.

### **3.1** Identifiability for conditionally independent $\overline{Y}$ and S

Suppose, for example, we have that  $\omega_{ij} = \{\bar{Y}_{ij}, S_{ij}\}$ , meaning that each study reported the sample means and sample standard deviations of a continuous outcome. We might make the hypothesis that  $\bar{Y}_{ij}^a \perp S_{ij}^a \mid N_{ij}^a, W_i$ . This independence assumption arises naturally from the distributional assumption that the  $Y_{ijk}^a \sim \mathcal{N}(M_i^a, (\Sigma_i^a)^2)$  because  $\bar{Y}_{ij}^a$  and  $S_{ij}^a$  are simply the sample mean and standard deviation in superpopulation  $\mathcal{P}_i$  when a is the treatment assigned. Asymptotically, we have that  $\bar{Y}_{ij}^a$  and  $S_{ij}^a$  are independent normal variables when the subject-level outcomes are drawn from a distribution with zero skew, such that  $E\{(Y_{ijk}^a)^3\} = 0$  (Ferguson, 1996, p. 46).

The joint counterfactual distribution can be decomposed as  $f(O_i^a) = f_1(O_i^a)f_2(O_i^a)$ where  $f_1(O_i^a) = Q_W(W_i)Q_{\bar{Y}}(\bar{Y}_{ij}^a \mid N_{ij}^a, W_i)$  and

$$f_{2}(O_{i}^{a}) = Q_{n}(n_{i} \mid W_{i})g_{A \setminus j}(A_{i \setminus j}^{a} \mid n_{i}, W_{i})Q_{N}(N_{ij}^{a} \mid A_{i \setminus j}^{a}, n_{i}, W_{i})Q_{S}(S_{ij}^{a} \mid N_{ij}^{a}, W_{i}) \times \prod_{j^{*} \neq j} Q_{\bar{Y},S}(\bar{Y}_{ij^{*}}^{a}, S_{ij^{*}}^{a} \mid N_{ij^{*}}^{a}, A_{ij^{*}}^{a}, W_{i})Q_{N}(N_{ij^{*}}^{a} \mid A_{i \setminus j}^{a}, n_{i}, W_{i}).$$

Let  $A_{i\setminus j} \neq a$  in the denominator of a summation be notational shorthand for sequentially setting the non-*j* arm(s)  $(A_{i\setminus j})$  to a treatment option distinct from *a*. The target of our analysis is the study arm counterfactual outcome under treatment *a*, or  $E(\bar{Y}_{ij}^a) = M^a$ . This mean can be written as

$$\begin{split} &\int_{W} \sum_{n_{i}=1}^{\infty} \sum_{A_{i\setminus j} \neq a} \sum_{N_{ij}=1}^{\infty} \int_{0}^{\infty} \int_{-\infty}^{\infty} \int_{0}^{\infty} \int_{-\infty}^{\infty} \bar{Y}_{ij}^{a} f(O_{i}^{a}) d\bar{Y}_{ij}^{a} dS_{ij}^{a} d\bar{Y}_{ij^{*}}^{a} dS_{ij^{*}}^{a} dW \\ &= \int_{W} \sum_{n_{i}=1}^{\infty} \sum_{A_{i\setminus j} \neq a} \sum_{N_{ij}=1}^{\infty} \int_{0}^{\infty} \int_{-\infty}^{\infty} \int_{0}^{\infty} \int_{-\infty}^{\infty} \bar{Y}_{ij}^{a} Q_{\bar{Y}}(\bar{Y}_{ij}^{a} \mid N_{ij}^{a}, W_{i}) d\bar{Y}_{ij}^{a} f_{2}(O_{i}^{a}) Q_{W}(W_{i}) dS_{ij}^{a} d\bar{Y}_{ij^{*}}^{a} dS_{ij^{*}}^{a} dW \\ &= \int_{W} \sum_{n_{i}=1}^{\infty} \sum_{A_{i\setminus j} \neq a} \sum_{N_{ij}=1}^{\infty} \int_{0}^{\infty} \int_{-\infty}^{\infty} \int_{0}^{\infty} E(\bar{Y}_{ij}^{a} \mid N_{ij}^{a}, W_{i}) f_{2}(O_{i}^{a}) Q_{W}(W_{i}) dS_{ij}^{a} d\bar{Y}_{ij^{*}}^{a} dS_{ij^{*}}^{a} dW \end{split}$$

where the integral for W can be a multiple integral, taken over the domain of potentially multivariate W. Now we note that for identically distributed and conditionally independent draws  $Y_{ijk}$ 

$$E(\bar{Y}_{ij}^a \mid N_{ij}^a, W_i) = E(\frac{1}{N_{ij}^a} \sum_{k=1}^{N_{ij}^a} Y_{ijk}^a \mid N_{ij}^a, W_i) = E(Y_{ijk}^a \mid W_i)$$

because we assume that the study size has no effect on the individual-level outcome. It follows that  $E(\bar{Y}_{ij}^a \mid N_{ij}^a, W_i)$  is conditionally independent of  $N_{ij}^a$ . The expression for  $M^a$ then simplifies to  $\int_W E(\bar{Y}_{ij}^a \mid W_i)Q_W(W_i)dW$ . In order for the conditional expectation to be estimable from the observed data, we require the unconfoundedness assumption  $\bar{Y}_{ij}^a \perp A_{ij} = a \mid W_i$ . With respect to Figure 1(b), this corresponds to having measured all components of  $W2_i$ . If this assumption holds in addition to the consistency of treatment for  $\bar{Y}_{ij}$ , we may write  $M^a = \int_W E(\bar{Y}_{ij} \mid W_i, A_{ij} = a)Q_W(W_i)dW$ . Therefore, this quantity is identifiable from the data.

Identifiability without assuming independence is possible, and we describe the additional causal assumptions required for this setting in the Supplementary Materials.

# 4 Estimation of the treatment-specific metapopulation mean outcome

### 4.1 G-Computation

G-Computation procedures based on the G-formula in Section 3 can be used to estimate the target parameter. Here we define a simple procedure resulting from the data requirement that the sample mean and standard deviation are independent within a study arm. It is also valid for binomial outcome data with no independence assumption if we take  $S_{ij} = \sqrt{Y_{ij}(1-Y_{ij})}$ . This procedure allows for simple frequentist estimation of the mean effect of treatment.

This procedure requires estimates for the conditional expectation  $E(\bar{Y}_{ij} \mid N_{ij}, A_{ij} = a, W_i)$  for a given value of treatment. First we must note that while the conditional mean of  $\bar{Y}_{ij}$  is independent of  $N_{ij}$ , its distribution is not. In particular, we have that

$$Var(\bar{Y}_{ij} \mid W_i, N_{ij}, A_{ij}) = \frac{1}{N_{ij}} Var(Y_{ijk} \mid W_i, N_{ij}, A_{ij}) = \frac{1}{N_{ij}} (\Sigma_i^{A_{ij}})^2.$$

Because  $S_{ij}^2$  is a consistent estimate of the superpopulation-level variance under treatment  $A_{ij}$ , we are able to estimate this variance.

A model for the regression on  $\bar{Y}_{ij}$  may be fit by pooling over all arms regardless of treatment assignment. In order to obtain the Best Linear Unbiased Estimator, we can weight by  $N_{ij}/S_{ij}$ . Using this model fit, we predict  $\hat{Y}_i^a = \hat{E}(\bar{Y}_{ij} \mid W_i, A_{ij} = a)$ , i.e. the predicted mean under treatment a for each study. The G-Computation estimate is then  $\hat{M}^a_{GCOMP2} = 1/N \sum_{i=1}^N \hat{Y}_i^a$ .

The standard error for the G-Computation estimate is usually computed through nonparametric bootstrap methods (Snowden et al., 2011). Bootstrap resampling must be done by resampling studies, rather than arms, similar to what is done in a study with clustering.

### 4.2 Arm-based Bayesian analysis

Here we propose arm-based Bayesian hierarchical mixed models that, given correct model specification, produce valid estimates of the mean outcome under treatment. Like G-Computation, they require model specification for the outcome process. Unlike G-Computation, they also require the specification of the entire likelihood and priors for each parameter. Bayesian methods allow the user to flexibly introduce study and treatment specific effects in addition to structured variance components. These methods may be preferable particularly if they prove to be more stable under small sample sizes.

For a continuous outcome under the independence assumption between each study arm's sample mean and standard error, a correct approach is similar to the arm-based approach for continuous outcomes given in, for example, Salanti et al. (2008). We assume that the arm-specific sample means are distributed as normal with mean equal to a linear specification conditional on fixed and random effects (potentially with a non-identity link). For instance, we might specify this mean as

$$E(\bar{Y}_{ij}) = \gamma^1 I(A_{ij} = 1) + \dots \gamma^4 I(A_{ij} = 4) + \gamma_W W_i + \eta_{ij}^{A_{ij}}, (\eta_{i1}^a, \dots, \eta_{in_i}^a) \sim MVN(0, R).$$

The parameters  $\gamma^a$  are treatment-specific means given separate (uninformative) normal priors for each treatment. The coefficient of the study-level covariate  $\gamma_W$  is made to be common across studies, and is given a normal prior distribution. The random effect parameter  $\eta^a_{ij}$  is specific to the study arm and treatment. The positive-definite variance covariance matrix R captures study-specific effects (correlation between the counterfactual outcomes under different treatments within a study) and heterogeneity across studies.

The baseline covariates  $W_i$  included in the model are assigned a likelihood with noninformative prior distributions placed on its parameters. Imputed covariates  $W_i^*$  are assigned the same likelihood. All prior distributions are noninformative or based on external beliefs. At each draw, we can then obtain an estimate of the conditional treatment-specific mean outcome by setting  $M_r^a(W_r^*) = \gamma_r^a + \gamma_{W,r}W_r^*$  where the subscript r represents the rth draw from the predictive posterior. The marginal estimate of  $M^a$  is then  $1/n_r \sum_r M_r^a(W_r^*)$  where  $n_r$  is the number of draws.

For binary outcomes, we base our procedure on the model described by Zhang et al. (2014) which we modified to allow for the inclusion of covariates and a relaxed specification of the link function in the regression model. Within a given study arm with  $N_{ij}$  individual binary outcomes  $Y_{ijk}$ , we assume that the outcomes are distributed as independent draws from a binomial with mean  $p_{ij}$ . This mean is modeled as normal with a study-specific random effect. Let  $N_{arm} = \sum_{i=1}^{N} n_i$  be the total number of treatment arms in the study.

The model for the mean can be specified, for instance, as

$$logit(p_{ij}) = \gamma^1 I(A_{ij} = 1) + \dots \gamma^4 I(A_{ij} = 4) + \gamma_W W_i + \eta_{ij}^{A_{ij}}, (\eta_{i1}^a, \dots, \eta_{in_i}^a) \sim MVN(0, R).$$

Note that the standard normal cumulative distribution link function, as used in Zhang et al. (2014) can alternatively be employed here. Additional details are identical to the continuous case, ensuring that estimates of the conditional mean outcome  $logit\{M_r^a(W_r^*)\} = \gamma_r^a + \gamma_{W,r}W_r^*$  are made using the corresponding link function.

### 4.3 Propensity score methods

Likelihood methods, such as G-Computation, require correct parametric specification of the outcome model, which may be difficult to specify. An alternative approach is to utilize propensity score methods, which require the estimation of a model for the treatment received by the arm. For a given treatment type a, let  $g_a(W_i)$  be an estimate of the probability  $P(a \in A_i \mid W_i)$ , called the generalized propensity score (Imbens, 2000).

Under weak unconfoundedness and correct specification of the model for treatment, generalized propensity score adjustment allows for unbiased estimation of the metapopulation mean outcome under treatment. A result of the balancing property of the generalized propensity score is weak unconfoundedness  $\bar{Y}_{ij} \perp A_{ij} = a \mid g_a(W_i)$  (Yang et al., 2015). We have that

$$E\{E(\bar{Y}_{ij} \mid g_a(W_i), A_{ij} = a)\} = E\{E(\bar{Y}_{ij}^a \mid g_a(W_i), A_{ij} = a)\} \text{ by consistency,}$$
$$= E\{E(\bar{Y}_{ij}^a \mid g_a(W_i))\} = E(\bar{Y}_{ij}^a) \text{ by weak unconfoundedness and the law of iterated expectations}$$

The conditional mean  $E(\bar{Y}_{ij} \mid g_a(W_i), A_{ij} = a)$ , can be estimated using a weighted regression across all study arms. For study *i*, let an estimate from this regression be denoted  $\hat{Y}_i^a$ . Then,  $\hat{M}_{PS}^a = 1/n \sum_{i=1}^N \hat{Y}_i^a$  is a corresponding estimate of  $M^a$  (Imbens, 2000).

A second popular propensity score approach is inverse probability of treatment weighting (IPTW). Let  $\bar{Y}_i^a$  represent the observed outcome in the arm of study *i* that received treatment *a* (or NA if study *i* did not receive treatment *a* in any arm). Let  $N_a$  be the number of studies that tested treatment *a*. The standard IPTW estimator for multiple treatments (Imbens, 2000) can be represented as

$$\hat{M}^a_{IPTW} = 1/N_a \sum_{i=1}^{N_a} \frac{\mathbb{I}(a \in A_i) \bar{Y}^a_i}{g_a(W_i)}.$$

Intuitively, this estimator takes a mean of  $\bar{Y}_{ij}$  with only the arms treated according to  $A_{ij} = a$ . It then adjusts this estimate to remove the confounding bias caused by the baseline variables. Consistency of this estimator can be shown as follows.

$$\hat{M}_{IPTW}^{a} \xrightarrow{P} E\left[\frac{\bar{Y}_{i}^{a}\mathbb{I}(a \in A_{i})}{g_{a}(W_{i})}\right] = E\left\{\bar{Y}_{i}^{a}E\left[\frac{\mathbb{I}(a \in A_{i})}{g_{a}(W_{i})}\middle|\bar{Y}_{i}^{a}, W_{i}\right]\right\} = E\left(\bar{Y}_{i}^{a}\right) = M^{a}.$$

Targeted Minimum Loss-based Estimation (TMLE) (van der Laan and Rubin, 2006; van der Laan and Rose, 2011) is a framework for the construction of semi-parametric estimators generally applied to the estimation of causal quantities. The following TMLE procedure requires that the sample means lie in (0, 1). If the means are bounded, then the scaled versions can be used in the following steps (Gruber and van der Laan, 2010). If natural bounds do not exist, then practical ones might be used. The TMLE procedure is carried out by first fitting a model for the expected value of the (scaled) arm-based means,  $E(\bar{Y}_{ij} \mid W_i, A_{ij} = a)$ . As in the linear G-Computation procedure, this model is weighted by  $N_{ij}/S_{ij}^2$ . For each arm in the study, we use this model to obtain  $\hat{Y}_i^a$ , predictions of the sample mean of each trial i under treatment a. These predictions are then updated by fitting a no-intercept logistic regression on studies where  $a \in A_i$  with outcome  $\bar{Y}_{ij}$ , offset  $logit(\hat{Y}_i^a)$ , and single covariate  $\mathbb{I}(a \in A_i)/g_a(W_i)$ , corresponding with the inverse probability weights. Denote the estimate of the coefficient from this regression as  $\hat{\epsilon}$ . The updated predictions are then  $\hat{Y}_i^{a,*} = \hat{Y}_i^a + \hat{\epsilon}/g_a(W_i)$ , which is calculated for each study. The final targeted estimate for  $M^a$  (after rescaling the predicted means, if necessary) is  $\hat{M}^{a}_{TMLE} = 1/N \sum_{i=1}^{N} \hat{\bar{Y}}^{a,*}_{ij}.$ 

Note that this TMLE is consistent under correct specification of the propensity score model or the model for the expected value of the mean outcome (the property of *double robustness*). If both of these models are correct, then TMLE is asymptotically efficient in the class of regular, asymptotically linear estimators. TMLE has often been observed to perform better in simulations than IPTW (Porter et al., 2011), although how it performs in the small-sample context of network meta-analysis is to be seen. In particular, when  $W_i$  has a high dimensionality compared to the number of trial arms given treatment a, the probability of treatment model for  $P(a \in A_i \mid W_i)$  might produce estimates with low values. In this case, the inverse probability weights  $\mathbb{I}(A_{ij} = a)/g_a(W_i)$  will be large, which may result in highly variable estimates for both IPTW and TMLE. Propensity score regression adjustment has been shown to perform better than IPTW in moderate-sized samples (Ertefaie and Stephens, 2010).

## 5 Simulation study

We undertook a simulation study to compare the results of the methods proposed in this article in comparison to alternative statistical approaches in order to observe stability and establish feasibility in a realistically data-sparse scenario. All of the data generated satisfy the unconfoundedness, no interference, and positivity assumptions. There is also only one version of each treatment, corresponding with the consistency assumption.

#### 5.1 Data generation

The data generation in the simulation studies follows the variable-ordering assumptions described in Section 3. For simplicity, we fix all simulated studies to have exactly two treatment arms. We are interested in estimating the mean outcome under treatment for each of four treatments of interest. For each study i = 1, ..., N, we generate the population average characteristic,  $W_i$  from a Poisson distribution with mean 2. The probabilities of receiving a given treatment are calculated conditional on the value of  $W_i$ . Two treatment options  $A_i$  are then sampled without replacement using the calculated probabilities. Treatments 2 and 4 are generated to be less likely to be chosen with larger  $W_i$ . The sample size  $N_i$  (which we allowed to be common to both arms in the study) is drawn from a Poisson distribution with mean a linear function of  $W_i$  and  $A_i$ . For the next stages, we took two approaches.

1. Normal outcome: For each subject within each arm, we draw a baseline covariate  $X_{ijk}$  from a Gaussian distribution with mean  $W_i$  and constant variance. We then sample subject-level random treatment effects (coefficients)  $\beta_{ijk}$  from a Gaussian with

a constant, treatment-specific mean and a small standard deviation. Specifically,

b = (0.8, 0.2, 1, -0.05) are the treatment-specific means;  $\beta_{ijk} \sim \mathcal{N}(b, 0.2)$  are sampled for each subject.

Let  $A_{ij}$  be represented as a vector of length 4 that indicates which treatment is applied to study *i*, arm *j*. Outcome values  $Y_{ijk}$  are drawn from a Gaussian with mean as a linear function of  $X_{ijk}$  and  $\beta_{ijk} * A_{ij}$  (the random treatment effect times the treatment received) with constant variance.

$$Y_{ijk} \sim \mathcal{N}(X_{ijk} + \beta_{ijk} * A_{ij}, 1)$$

2. Binomial outcome: For each subject within each arm,  $X_{ijk}$  is drawn from a Gaussian distribution with mean  $W_i$  and constant variance. Subject-specific random treatment effects  $\beta_{ijk}$  are sampled from a Gaussian with treatment-specific means (as in Simulation 1). The binary outcomes are then sampled from a binomial distribution with probability of success generated linearly on the logit scale, conditional on  $X_{ijk}$  and  $\beta_{ijk} * A_{ij}$ ,

$$Y_{ijk} \sim \mathcal{B}in\{\exp(-2 + X_{ijk}/2 + \beta_{ijk} * A_{ij})\}.$$

The results from each study arm are calculated by taking the mean and standard deviation of  $Y_{ijk}$  within each arm. For the normal outcome, the true treatment-specific superpopulation means are  $M^1 = 2.80, M^2 = 2.20, M^3 = 3.00, M^4 = 1.95$ . For the binomial outcome, the treatment-specific superpopulation means can be derived through multiple integration or numerical approximation. They are approximately  $M^1 = 0.45, M^2 =$  $0.33, M^3 = 0.50, M^4 = 0.29$ . In this simulation study, we are interested in estimating a subset of the contrasts between the treatments, specifically marginal mean differences  $M^2 - M^1 = -0.60, M^3 - M^1 = 0.20, M^4 - M^1 = -0.85$  for Simulation 1 and marginal risk ratios  $M^2/M^1 = 0.73, M^3/M^1 = 1.09, M^4/M^1 = 0.63$  for Simulation 2. Note that random effects were not generated in this simple simulation study.

We note here that the methods presented in Section 4 will be asymptotically unbiased under the conditions of the simulation study, i.e. for large values of N. Therefore, the goal of the simulation study is to assess numerically the finite sample properties of the various estimators for numbers of studies that are generally seen in the literature for network meta-analysis.

### 5.2 Simulation results

We tested two frequentist linear random effects models (Salanti et al., 2008): "RE arm" models the arm-specific means with a random study-specific intercept, and "RE Contrast" takes the contrast of interest as the outcome and includes a random effect specific to the contrast. The random effects models for the contrasts are always linear with linear link functions, which allows us to interpret the coefficient estimates as the estimate of the treatment-specific mean or contrast. All models are inverse weighted by the standard error of the outcome. These models were run using the R library lme4 (Bates et al., 2014), with standard errors taken from the output. The adapted causal methods utilized are described in Sections 4.1 and 4.3. Propensity scores were fit with logistic regressions, and conditional expectations of the outcome were fit with weighted linear or logistic regressions. The standard errors were calculated with the nonparametric bootstrap, with 1000 resamples. The arm-specific Bayesian models were implemented in OpenBUGS (Lunn et al., 2000) with the R library BRugs (Thomas et al., 2006). They were run with and without the random effects described in Section 4.2. In Simulation 2, we also ran the arm-specific random effects model described in Zhang et al. (2014), unadjusted for the confounding variable. More details about the simulation study implementations can be found in the Supplementary Materials.

Tables 1 and 2 correspond to the results from Simulations 1 and 2, respectively. In each table, we present statistics describing the quality of the estimation of all contrasts with treatment 1. These statistics are the percent observed bias ("% Bias"), the standard deviation of the estimates over the simulated data ("SE (MS)"), the estimated standard error ("SE (Est)"), and the percentage of the 95% confidence intervals that capture the true effect size ("% Cov"). The percentages are rounded to the nearest percent and the standard errors are rounded to two decimal places.

In Simulation 1, the subject-specific outcomes were generated from a Gaussian distribu-

tion with a linear specification. This led to independence between the within-study sample means and standard deviations, resulting in identifiability of the target parameters. The contrasts of interest were the average treatment effects. The two frequentist random effects models performed similarly, with little observed bias but moderate undercoverage. The random effects model for the contrasts generally had the higher standard error compared to the random effects model for the arms. G-Computation showed no bias, the lowest standard errors and near-optimal coverage. Generalized propensity score adjustment ("PS") also had low observed bias, somewhat higher standard error, and slight overcoverage. TMLE and IPTW, which both use inverse weighting of the propensity score, appeared to be sensitive to rare treatment; both displayed considerable bias for the contrast of treatment 4 vs 1. The bootstrap standard error estimates for TMLE and IPTW were often very different from the Monte Carlo standard errors. Otherwise, TMLE performed well. The Bayesian methods both demonstrated no bias with low standard errors. The model without random effects produced optimal coverage (at the same level as G-Computation). However, the estimated standard errors of the random effects versions were double the Monte Carlo standard errors and correspondingly resulted in inflated confidence intervals and overcoverage.

In Simulation 2, the subject-specific outcomes were generated from a logistic regression model with logit link. The contrasts of interest were the causal risk ratios for the outcome. PS often diverged when a weighted logistic regression outcome model was used, so the results below are unweighted. All methods produced results with near-zero bias, except for IPTW which had higher bias when one of the treatments being contrasted was sometimes rare (specifically, treatments 2 and 4). The random effects models produced very small standard errors, resulting in undercoverage. G-Computation and PS produced no bias and near-optimal coverage, except when treatment 4 (the least prevalent treatment) was being contrasted. TMLE and IPTW had the highest standard errors, although this corresponded with optimal coverage for TMLE. The Bayesian method proposed in this paper did not produce bias but did produce inflated standard errors, so that its coverage was always 100% (with or without random effects). The method by Zhang et al. (2014) was slightly biased for two contrasts (presumably due to the lack of control for W) and also resulted in 100% coverage for the third contrast where it produced no bias.

A third simulation study was performed for skewed continuous outcomes with dependence between the arm-specific sample means and standard deviations. In this setting, all of the methods tested were heavily biased. The results are available in the Supplementary Materials, Section 3.

# 6 Efficacy of antibiotic use on methicillin-resistant *Staphylococcus aureus* infection

In this section, we present a re-analysis of the data presented in the introduction in order to estimate the *causal* relative risk of clinical success at test of cure for each antibiotic compared to vancomycin. In the original manuscript, Bally et al. (2012) contrast six alternative antibiotics against vancomycin. Details about the systematic review parameters and each of the selected studies can be found in the original paper. For our analysis, we chose to compare vancomycin with the two most prevalent alternatives: telavancin and linezolid. Specifically, we kept the data from all study arms that evaluated any of these three therapies, leaving us with 29 study arms. Because all studies had a vancomycin arm, we retained a representative arm from each study (thereby not inducing any informative censoring of studies). We then ran five methods to obtain estimates of the counterfactual relative risk of both contrasts with the comparator vancomycin. The methods are 1) a random effects regression for the arm-specific study outcomes using a log-link and a studyspecific intercept, 2) G-Computation where a random effects logistic regression weighted by the inverse standard errors is used to predict the conditional mean outcomes, 3) propensity score adjustment where a logistic regression is used to estimate the propensity score, 4) TMLE with a weighted logistic random effects model for the outcome and a logistic regression for the propensity score, and 5) the random effects Bayesian model described in Section 4.2. IPTW behaved erratically and was not included in this example. To estimate the standard errors and confidence intervals, the built-in functions in the library lme4 were used for the random effects model, the nonparametric bootstrap (1000 resamples of 29 arms with replacement) was used for G-Computation, propensity score adjustment and TMLE, and the variability of the posterior samples was used for the Bayesian model. The Bayesian

model was fit in OpenBUGS and BRugs with vague priors placed on all parameters and hyperparameters. Convergence of the Markov chain Monte Carlo sampler was assessed through graphical diagnostic plots. Convergence was attained after a burn-in of 100,000 draws and estimation was based on the subsequent 100,000 draws (thinned by taking one out of five draws from 500,000 samples).

The numerical results of the network meta-analysis are presented in Figure 2. We also included the results of the studies that contrasted the two treatments directly. For the comparison of telavancin versus vancomycin, all estimators include the null in the confidence interval, and the estimates of the relative risk are all close to 1, indicating near equivalence of treatments. Notably, the confidence intervals for the random effects regression and G-Computation are very small. The confidence intervals for the other estimators are much wider, corresponding with standard errors that are roughly ten times larger. For the comparison of linezolid versus vancomycin, the random effects regression and G-Computation agree on the superiority of linezolid. However, while TMLE agrees with the effect estimate, its confidence interval included the null. Propensity score adjustment concludes the opposite, but its conclusions were highly sensitive to outcome model specification. The results for G-Computation were stable under interaction between the baseline variables and changing the link of the logistic regression to probit.

If we are to interpret the summary statistics as estimates of the relative causal effects of antibiotic choice on successful treatment, the causal assumptions in Section 2.4 need to be satisfied. *No interference*: We firstly assume that the treatments contrasted in one study did not affect the counterfactual outcomes in another study. Each of the studies evaluated the clinical efficacy of the treatments, which is defined on patients who had received at least one dose of the study drug. Because randomized treatment was first-line therapy (administered intravenously in-hospital) and the success of treatment was determined clinically, each trial estimated the relative effect under full adherence. No interference is credible in this case because all subjects were already suspected or confirmed to have MRSA upon entry to the study. Therefore, the choice of treatment in the other arm wouldn't have an effect on existing infections nor the success of treatment. *Unconfoundedness*: The unconfoundedness assumption relies on whether year and infection site were sufficient to



Direct and NMA contrasts between linezolid and vancomvcin



Figure 2: Risk ratio estimates and confidence intervals for clinical success at test of cure for all studies with direct comparisons and all network meta-analysis methods for the contrasts between a) telavancin and vancomycin and b) linezolid and vancomycin. Risk ratio values below one indicate superiority of vancomycin.

control for confounding at the study-level. This assumption would be violated if demographic variables involved in the treatment comparison decision at the study design stage are also prognostic. Prognostic markers such as diabetes and peripheral vascular disease (for cSSTI) and mechanical ventilation, APACHE II score, clinical markers of severity, and presence of organ dysfunction (for pneumonia) are unlikely to determine the choice of initial therapy (Lipsky et al., 2011; Niederman, 2010) and therefore do not confound the analysis. *Consistency*: The dosage regimens varied somewhat across studies but were all considered to be at therapeutic levels. This heterogeneity in regimens may arguably have no impact on the outcome. However, the length of time to the evaluation time point for each treatment type varied within and between studies (e.g. 7-14 days for telavancin versus 12-28 days for linezolid). If this corresponds to meaningfully different treatment durations (and/or periods of time lapsed before evaluation), this would indicate different definitions of interventions across studies, and thus a violation of the consistency assumption.

## 7 Discussion

In this paper, we nonparametrically define the parameter of interest in a network metaanalysis with direct and indirect comparisons using the counterfactual framework that is commonly used in causal inference. This definition of the parameter of interest is modelindependent. Such an approach allows for a straight-forward description of what is being estimated, which is accessible even without an understanding of the estimation methods being used.

The estimators introduced in this paper allow for prognostic variables affecting the choice of treatment at the study design level. If all treatments are chosen completely at random (or if only two treatments have ever been available to compare) then a standard unadjusted analysis using those arms assigned the desired treatments would be consistent. We also assume that the DAG structure in Figure 1(a) applies.

We have presented a set of conditions under which identifiability of the parameter of interest is possible. Identifiability allows for a clear description of when the parameter of interest can and can not be estimated. The assumptions that we made allowed for the simplification of the relevant components of the observed data likelihood so that within-arm inference is possible. Alternative approaches for identification might involve, for instance, 1) specifying the contrast as the "treatment of interest" (rather than use the arm-specific treatment as we did and 2) allowing for within-study interference. The benefits of our approach include the availability of semiparametric modeling to estimate the nonparametrically defined parameters of interest. The methods we describe can be made more flexible by using ensemble learning to combine multiple low-dimensional parametric models in G-Computation or TMLE. This approach would allow for reduced dependence on arbitrarily specified parametric models.

For the analysis of continuous individual-level outcomes, we assumed independence between the sample mean and standard deviation within each study arm. While we chose to present our identifiability argument under this assumption, it is not ultimately necessary. However, it is not straight-forward to propose a valid Monte Carlo or Bayesian approach to the setting with dependent sample means and standard deviations. Our initial efforts (results not presented) have shown that modeling  $\bar{Y}_{ij}$  and  $S_{ij}$  as bivariate normal (the true asymptotic distribution under large study samples where the outcomes are skewed) produces results that are highly sensitive to model specification. This we leave to future work. In some cases, it may be alternatively possible to transform the individual-level data to remove the skew, proceed with the computations, and then retransform the mean outcomes under each treatment of interest. But this relies on access to each study's raw data. As shown in Simulation study 3 (in the Supplementary Materials), all proposed estimators accrue high bias when a heavy skew is present.

In the simulation study, we show that estimators adapted from the causal inference literature can produce valid estimates of effect contrasts under the identifiability conditions described. In particular, G-Computation, generalized propensity score adjustment, and TMLE might lend themselves well to network meta-analysis, which is characterized by small sample sizes and low prevalence for certain treatments. Causal methods using inverse weighting of the propensity score (IPTW and TMLE) were seen to be sensitive to rare treatment assignment. However, adjustment methods may improve their performance. The Bayesian method that was proposed in this manuscript also performed well, although overparametrization through the unnecessary addition of random effects led to inflated confidence intervals and overcoverage. However, this may be a property of Bayesian estimators in small sample settings as the method by Zhang et al. (2014) also showed evidence of this trait. In contrast, the frequentist random effects models underestimated the standard errors and did not perform well in terms of confidence interval coverage. We did not compare methods that estimated a parameter that did not correspond to the contrast-type targeted in the simulation study. For instance, we did not compare our methods to Bayesian models that estimate an adjusted odds ratio. For a discussion of the misinterpretation of network meta-analytical summaries, see Zhang et al. (2014).

The application we presented compared the results of random effects regression, G-Computation, propensity score adjustment, TMLE and the Bayesian model in a network meta-analysis of the relative efficacy of treatment options for MRSA infection. The random effects regression and G-Computation produced very small confidence intervals, contrasting the large confidence intervals for the other methods. We noted the poor stability of IPTW and propensity score adjustment in this example. More simulation studies under model misspecification are needed to assess whether these methods should be recommended in practice. Using this data example, we also demonstrated how the causal assumptions should be listed and critiqued in order to stimulate discussion about the appropriateness of causal interpretations in specific contexts.

The framework we present formally assumes that we are restricting our analyses to studies evaluating a common parameter-type. In the partial adherence setting for example, it does not allow for the inclusion of studies that estimate an intent-to-treat (ITT) effect aggregated with those that estimate an adherence-adjusted effect. (Estimation of the adherence-adjusted effect is described in Hernán and Hernández-Díaz 2012; Fischer et al. 2011.) These different types of analyses use different definitions of treatment: assignment of treatment versus full adherence to treatment. The same restriction applies to the results of observational studies if the treatment effect type estimated in the observational study is not the same as in the clinical trials. Specifically, treatment adherence and outcome need to be defined identically across studies, and all studies must estimate the same mean treatment-specific counterfactual outcome. To avoid selection bias, we can include all types of studies in the systematic review, but artificially censor the outcomes of those that do not estimate the desired parameter-type of interest. Censored studies might then be considered to be "missing at random" and their baseline information should be included in the analysis.

Additional discussion is required regarding the validity of the aggregation of ITT parameters. In order to do so, we must assume no interference, which is invalid for ITT under treatment switching (or differential availability of alternative treatment) in addition to many settings involving exposure to infectious disease. Furthermore, consistency may be violated if different versions of treatment assignment (including the settings under which treatment was assigned) affect adherence patterns and if differential adherence affects the mean outcome of the arm.

In addition to the issues described in this paper, there are many other concerns about the coherency of aggregating study outcomes in various settings. For instance, one might question the independence between RCTs happening close in time, or the systematic review inclusion criteria. We believe our framework provides additional structure to the ongoing discussion about the validity of network meta-analysis and will help stimulate solutions to the remaining challenges.

## References

- Alonso, A., W. Van der Elst, G. Molenberghs, M. Buyse, and T. Burzykowski (2014). On the relationship between the causal-inference and meta-analytic paradigms for the validation of surrogate endpoints. *Biometrics*.
- Bally, M., N. Dendukuri, A. Sinclair, S. P. Ahern, M. Poisson, and J. Brophy (2012). A network meta-analysis of antibiotics for treatment of hospitalised patients with suspected or proven meticillin-resistant *Staphylococcus aureus* infection. *International Journal of Antimicrobial Agents* 40, 479–495.
- Bates, D., M. Maechler, B. Bolker, and S. Walker (2014). *lme4: Linear mixed-effects models using Eigen and S4*. R package version 1.1-7.
- Caldwell, D. M., A. E. Ades, and J. P. T. Higgins (2005). Simultaneous comparison of multiple treatments: combining direct and indirect evidence. *BMJ 331*, 897–900.
- Cole, S. R. and C. E. Frangakis (2009). The consistency statement in causal inference: A definition or an assumption? *Epidemiology* 20(1), 3–5.
- Cope, S., J. Zhang, S. Saletan, B. Smiechowski, J. P. Jansen, and P. Schmid (2014). A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. *BMC Medicine* 12(93).
- Dias, S., A. J. Sutton, A. E. Ades, and N. J. Welton (2013). A generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. *Medical Decision Making 33*(5), 607–617.
- Ertefaie, A. and D. A. Stephens (2010). Comparing approaches to causal inference for longitudinal data: Inverse probability weighting versus propensity scores. *The International Journal of Biostatistics* 6(2), 1557–4679.

- Ferguson, T. S. (1996). A Course in Large Sample Theory. Texts in Statistical Science. Chapman & Hall/CRC.
- Fischer, K., E. Goetghebeur, B. Vrijens, and I. R. White (2011). A structural mean model to allow for noncompliance in a randomized trial comparing 2 active treatments. *Biostatistics* 12(2), 247–257.
- Gail, M. H., S. Wieand, and S. Piantadosi (1984). Biased estimates of treatment effect in randomized experiments with nonlinear regressions and omitted covariates. *Biometrika* 71(3), 431–444.
- Gruber, S. and M. J. van der Laan (2010). A targeted maximum likelihood estimator of a causal effect on a bounded continuous outcome. The International Journal of Biostatistics 6(1), Article 26.
- Hernán, M. A. and S. Hernández-Díaz (2012). Beyond the intention to treat in comparative effectiveness research. *Clinical trials* 9(1), 48–55.
- Imbens, G. W. (2000). The role of the propensity score in estimating dose-response functions. *Biometrika* 87(3), 706–710.
- Jansen, J. P., C. H. Schmid, and G. Salanti (2012). Directed acyclic graphs can help understand bias in indirect and mixed treatment comparisons. *Journal of Clinical Epidemiology* 65(7), 798–807.
- Lipsky, B. A., K. M. Itani, J. A. Weigelt, W. Joseph, C. M. Paap, A. Reisman, D. E. Myers, and D. B. Huang (2011). The role of diabetes mellitus in the treatment of skin and skin structure infections caused by methicillin-resistant staphylococcus aureus: results from three randomized controlled trials. *International Journal of Infectious Diseases* 15(2), e140–e146.
- Liu, C., A. Bayer, S. E. Cosgrove, R. S. Daum, S. K. Fridkin, R. J. Gorwitz, S. L. Kaplan, A. W. Karchmer, D. P. Levine, B. E. Murray, M. J. Rybak, D. A. Talan, and H. F. Chambers (2011). Clinical practice guidelines by the infectious diseases society of america

for the treatment of methicillin-resistant staphylococcus aureus infections in adults and children. *Clinical Infectious Diseases* 52(3), e18–e55.

- Lu, G. and A. E. Ades (2004). Combination of direct and indirect evidence in mixed treatment comparisons. *Statistics in Medicine* 23(20), 3105–3124.
- Lu, G. and A. E. Ades (2006). Assessing evidence inconsistency in mixed treatment comparisons. *Journal of the American Statistical Association 101* (474), 447–459.
- Lumley, T. (2004). Network meta-analysis for indirect treatment comparisons. *Statistics* in Medicine 21, 23132324.
- Lunn, D. J., A. Thomas, N. Best, and D. Spiegelhalter (2000). Winbugs a bayesian modelling framework: concepts, structure, and extensibility. *Statistics and Computing 10*, 325–337.
- Niederman, M. S. (2010). Hospital-acquired pneumonia, health care-associated pneumonia, ventilator-associated pneumonia, and ventilator-associated tracheobronchitis: definitions and challenges in trial design. *Clinical Infectious Diseases 51 Suppl 1*, S12–S7.
- Pearl, J. (2009). Causality: Models, Reasoning, and Inference (2 ed.). Cambridge University Press.
- Porter, K. E., S. Gruber, M. J. van der Laan, and J. S. Sekhon (2011). The relative performance of targeted maximum likelihood estimators. *The International Journal of Biostatistics* 7(1), 1–34.
- Robins, J. M. (1986). A new approach to causal inference in mortality studies with a sustained exposure period – application to control of the healthy worker survivor effect. *Mathematical Modelling* 7, 1393–1512.
- Robins, J. M. (1988). Confidence intervals for causal parameters. Statistics in Medicine 7(7), 773–785.
- Rubin, D. B. (1974). Estimating causal effects of treatments in randomized and nonrandomized studies. *Journal of Educational Psychology* 66(5), 688–701.

- Rubin, D. B. (1980). Randomization analysis of experimental data: The fisher randomization test comment. Journal of the American Statistical Association 75(371), 591–593.
- Salanti, G., J. P. T. Higgins, A. E. Ades, and J. P. A. Ioannidis (2008). Evaluation of networks of randomized trials. *Statistical Methods in Medical Research* 17, 279–301.
- Salanti, G., V. Marinho, and J. P. T. Higgins (2009). A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. *Journal of Clinical Epidemiology 62*, 857–864.
- Snowden, J. M., S. Rose, and K. M. Mortimer (2011). Implementation of g-computation on a simulated data set: Demonstration of a causal inference technique. *American Journal* of Epidemiology 173(7), 731–738.
- Thomas, A., B. O'Hara, U. Ligges, and S. Sturtz (2006). Making bugs open. R News 6(1), 12–17.
- van der Laan, M. J. and S. Rose (2011). Targeted Learning: Causal Inference for Observational and Experimental Data. Springer Series in Statistics. Springer.
- van der Laan, M. J. and D. Rubin (2006). Targeted maximum likelihood learning. *The International Journal of Biostatistics* 2(1), Article 11.
- Yang, S., G. Imbens, Z. Cui, D. Faries, and Z. Kadziola (2015). Propensity score matching and subclassification with multivalued treatments.
- Zhang, J., B. P. Carlin, J. D. Neaton, G. G. Soon, L. Nie, R. Kane, B. A. Virnig, and H. Chu (2014). Network meta-analysis of randomized clinical trials: Reporting the proper summaries. *Clinical Trials* 11, 246–262.

uics, 1000 siniu	alleu ua	uascus).					
	Treatment 2 vs 1, $M^2 - M^1 = -0.6$						
Method	% Bias	SE(MC)	SE (Est)	$\%~{\rm Cov}$			
RE Arm	-1	0.16	0.11	79			
RE Contrast	0	0.21	0.19	81			
G-Comp	0	0.04	0.04	92			
$_{\rm PS}$	-4	0.24	0.26	99			
IPTW	41	0.57	0.61	88			
TMLE	-6	0.33	0.46	97			
Bayesian	0	0.05	0.11	100			
Bayesian (no RE)	0	0.04	0.04	95			
	Treatment 3 vs 1, $M^3 - M^1 = 0.20$						
Method	% Bias	SE(MC)	SE (Est)	$\%~{\rm Cov}$			
RE Arm	1	0.16	0.13	85			
<b>RE</b> Contrast	1	0.18	0.17	86			
G-Comp	-1	0.04	0.04	92			
PS	-17	0.28	0.33	98			
IPTW	-4	0.10	0.25	98			
TMLE	-1	0.15	0.28	99			
Bayesian	-2	0.05	0.09	100			
Bayesian (no RE)	-1	0.04	0.04	94			
	Treatment 4 vs 1, $M^4 - M^1 = -0.85$						
Method	% Bias	SE (MC)	SE (Est)	$\%~{\rm Cov}$			
RE Arm	0	0.19	0.11	74			
RE Contrast	0	0.25	0.19	79			
G-Comp	0	0.04	0.04	90			
PS	12	0.28	0.27	99			
IPTW	81	0.76	0.62	64			
TMLE	-45	0.87	0.73	86			
Bayesian	0	0.05	0.11	100			
Bayesian (no RE)	0	0.04	0.04	95			

Table 1: Simulation 1: Quality of treatment contrast estimation with a Gaussian outcome(N = 15 two-arm studies, 1000 simulated datasets).

	Treatment 2 vs 1, $M^2/M^1 = 0.73$					
Method	% Bias	SE (MC)	SE (Est)	% Cov		
RE Arm	-5	0.04	0.03	61		
RE Contrast	-7	0.05	0.03	39		
G-Comp	0	0.02	0.02	91		
PS	-1	0.03	0.04	92		
IPTW	-9	0.16	0.18	81		
TMLE	0	0.09	0.18	98		
Bayesian	-2	0.03	0.08	100		
Bayesian (no RE)	-3	0.02	0.07	100		
Zhang	-6	0.07	0.09	98		
	Treat	Treatment 3 vs 1, $M^3/M^1 = 1.09$				
Method	% Bias	SE (MC)	SE (Est)	% Cov		
RE Arm	1	0.05	0.04	86		
RE Contrast	2	0.07	0.04	71		
G-Comp	0	0.02	0.02	93		
PS	0	0.04	0.04	92		
IPTW	0	0.05	0.14	98		
TMLE	0	0.06	0.13	95		
Bayesian	1	0.03	0.06	100		
Bayesian (no RE)	1	0.02	0.04	100		
Zhang	0	0.04	0.08	100		
	Treatment 4 vs 1, $M^4/M^1 = 0.63$					
Method	% Bias	SE (MC)	SE (Est)	$\% \ {\rm Cov}$		
RE Arm	-11	0.04	0.03	35		
RE Contrast	-12	0.05	0.03	24		
G-Comp	0	0.03	0.02	89		
PS	-3	0.03	0.04	88		
IPTW	-30	0.20	0.18	51		
TMLE	7	0.29	0.18	93		
Bayesian	-3	0.03	0.08	100		
Bayesian (no RE)	-4	0.02	0.07	100		
Zhang	-16	0.10	0.09	92		

Table 2: Simulation 2: Quality of treatment contrasts estimation with a binary outcome (N = 15 two-arm studies, 1000 simulated datasets).